B2M and neoplasm: Notably, we found that patients whose tumours had impaired beta 2 microglobulin (B2M) expression responded to ICB treatment, even in the absence of antigen-presenting machinery, and the same results were reported in mice lacking the CD8 + T cell compartment [46].